Drug Profile
Salubrin HF - Pherin Pharmaceuticals
Alternative Names: PH80 - Pherin Pharmaceuticals; PH80-HF; PH80-HF NS; Salubrin HFLatest Information Update: 06 Feb 2023
Price :
$50
*
At a glance
- Originator Pherin Pharmaceuticals
- Class Antimigraines
- Mechanism of Action Neurotransmitter receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hot flashes
- Preclinical Migraine
Most Recent Events
- 02 Feb 2023 Pherin Pharmaceuticals has been acquired by VistaGen Therapeutics
- 08 Jun 2020 Preclinical trials in Migraine in USA (unspecified route), prior to June 2020 (Pherin Pharmaceuticals pipeline, June 2020)
- 07 Oct 2015 Efficacy and adverse events data from a phase II trial in Hot flashes released by Pherin Pharmaceutical